A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled Study to Assess the Efficacy and Safety of Nexagon (NEXAGON) Applied Topically in Subjects With Corneal Persistent Epithelial Defects Resulting From Severe Ocular Chemical and or Thermal Injuries
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Lufepirsen (Primary)
- Indications Chemically-induced disorders; Corneal injuries
- Focus Adverse reactions; Therapeutic Use
- Acronyms EXPEDE
- Sponsors Amber Ophthalmics; OcuNexus Therapeutics
Most Recent Events
- 23 Oct 2024 Status changed from recruiting to discontinued.
- 25 Aug 2022 Planned End Date changed from 1 Aug 2021 to 1 Mar 2023.
- 25 Aug 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Mar 2023.